The estimated Net Worth of Joseph William Stauffer is at least $233 mil dollars as of 17 October 2018. Joseph Stauffer owns over 11,442 units of Durect Corp stock worth over $3,140 and over the last 15 years Joseph sold DRRX stock worth over $230,327.
Joseph has made over 3 trades of the Durect Corp stock since 2015, according to the Form 4 filled with the SEC. Most recently Joseph sold 11,442 units of DRRX stock worth $230,327 on 17 October 2018.
The largest trade Joseph's ever made was selling 11,442 units of Durect Corp stock on 17 October 2018 worth over $230,327. On average, Joseph trades about 1,544 units every 117 days since 2009. As of 17 October 2018 Joseph still owns at least 2,000 units of Durect Corp stock.
You can see the complete history of Joseph Stauffer stock trades at the bottom of the page.
Joseph's mailing address filed with the SEC is C/O CARA THERAPEUTICS, INC.,, ONE PARROTT DRIVE, SHELTON, CT, 06484.
Over the last 21 years, insiders at Durect Corp have traded over $528,010 worth of Durect Corp stock and bought 19,954,650 units worth $23,296,708 . The most active insiders traders include April Fund Ltd21 April Fund..., Eagle Investment Management..., eFelix Theeuwes. On average, Durect Corp executives and independent directors trade stock every 55 days with the average trade being worth of $468,485. The most recent stock trade was executed by Judith J. Robertson on 18 August 2022, trading 80,942 units of DRRX stock currently worth $68,801.
durect is a specialty pharmaceuticals company with expertise in drug discovery, drug delivery and drug development, applying those skills primarily to therapeutics in the fields of pain management, acute organ injury and metabolic diseases. durect’s proprietary oral, transdermal and injectable depot delivery technologies enable new indications and superior clinical/commercial attributes such as improved abuse deterrence, convenience, adherence, efficacy and safety for small molecule and biologic drugs. late stage development programs of this nature include remoxy® and posidur™. durect’s epigenomic regulator program includes the lead molecule dur-928 in phase 1 clinical testing. dur-928 is an endogenous small molecule that is an epigenomic modulator of cellular activities involved in lipid homeostasis, metabolic disease, inflammation and cell survival. for more information, please visit www.durect.com. we also manufacture and sell two commercial product lines: • alzet® osmotic pumps use
Durect Corp executives and other stock owners filed with the SEC include: